Loading...
XSHE300534
Market cap364mUSD
Jan 06, Last price  
8.80CNY
1D
5.52%
1Q
-20.43%
Jan 2017
-51.72%
IPO
42.59%
Name

Gansu Longshenrongfa Pharmaceutical Industry Co Ltd

Chart & Performance

D1W1MN
XSHE:300534 chart
P/E
43.30
P/S
2.47
EPS
0.20
Div Yield, %
0.14%
Shrs. gr., 5y
0.02%
Rev. gr., 5y
39.67%
Revenues
1.08b
+161.36%
133,365,959212,676,485274,889,691301,575,286277,360,875269,681,016269,587,022203,165,802239,003,313254,899,757287,813,045413,246,8041,080,050,028
Net income
62m
+138.70%
13,897,07225,255,87440,912,08860,424,35060,677,16447,252,33917,112,16512,277,84112,777,5011,831,125025,826,45761,647,653
CFO
97m
+744.72%
0035,917,46539,007,99430,601,50313,135,424010,232,91328,208,54343,500,88051,134,88411,426,98596,526,292
Dividend
Sep 27, 20240.02 CNY/sh
Earnings
May 15, 2025

Profile

Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd researches, develops, produces, and sells Chinese medicines, health food, and APIs. It offers Yuanhu Analgesic dropping pills, Qiwei Wenyang capsules, Maxing cough capsules, Shuxinning tablets, Panax notoginseng pills, Anti-inflammatory and gallbladder tablets, Children's Qingfei cough tablets, Pediatric Qinggan tablets, Suanzaoren oil dropping pills, Xiaoshuan Tongluo tablets, Xiaoyanlidan tablets, Compound Danshen tablets, and Astragalus Angelica capsules, as well as berberine tannin films. The company also engages in the planting, acquisition, processing, sales, and commercial distribution of Chinese medicinal materials; investment and management of project; and import, sales, logistics, and export of pharmaceutical. Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd was founded in 2002 and is based in Lanzhou, China.
URL
http://www.lsrfzy.com/
IPO date
Sep 13, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,080,050
161.36%
413,247
43.58%
Cost of revenue
918,360
359,429
Unusual Expense (Income)
NOPBT
161,690
53,818
NOPBT Margin
14.97%
13.02%
Operating Taxes
13,168
1,904
Tax Rate
8.14%
3.54%
NOPAT
148,523
51,914
Net income
61,648
138.70%
25,826
 
Dividends
(3,817)
Dividend yield
0.13%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
30,033
Long-term debt
117,029
Deferred revenue
26,445
22,268
Other long-term liabilities
1
Net debt
(196,082)
(264,240)
Cash flow
Cash from operating activities
96,526
11,427
CAPEX
Cash from investing activities
(126,359)
Cash from financing activities
(50,719)
FCF
145,313
48,397
Balance
Cash
288,945
97,834
Long term investments
54,200
166,406
Excess cash
289,143
243,577
Stockholders' equity
614,167
531,643
Invested Capital
592,159
516,957
ROIC
26.78%
10.04%
ROCE
18.34%
7.08%
EV
Common stock shares outstanding
303,384
303,345
Price
9.87
11.27%
8.87
-39.74%
Market cap
2,994,402
11.29%
2,690,670
-39.74%
EV
2,876,124
2,443,485
EBITDA
191,592
73,838
EV/EBITDA
15.01
33.09
Interest
4,063
30
Interest/NOPBT
2.51%
0.06%